Contact Us
Drug Search Results
More Filters [+]

Rilotumumab

Alternative Names: rilotumumab, amg 102, amg102
Latest Update: 2024-08-23
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: C-Met Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rilotumumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Gastrointestinal Cancer|Esophageal Cancer|Adenocarcinoma|Squamous Cell Carcinoma

Phase 2: Glioblastoma|Gastrointestinal Cancer|Colorectal Cancer|Non-Small-Cell Lung Cancer|Glioma|Mesothelioma|Sarcoma|Gliosarcoma|Prostate Cancer|Esophageal Cancer|Adenocarcinoma|Small Cell Lung Cancer|Peritoneal Cancer|Brain Cancer|Ovarian Cancer|Renal Cell Carcinoma

Phase 1: Gastrointestinal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MEGA

P2

Completed

Unknown

2017-07-06

2011-004923-11

P3

Completed

Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer

2015-08-07

RILOMET-2

P3

Terminated

Gastrointestinal Cancer

2015-06-01

Lung-MAP

P3

Terminated

Squamous Cell Carcinoma

2015-01-12

Recent News Events

Date

Type

Title

06/01/2023

PubMed

 Computational Drug Discovery in Ankylosing Spondylitis-Induced Osteoporosis Based on Data Mining and Bioinformatics Analysis.

01/11/2023

PubMed

 Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.

04/11/2022

PubMed

 Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions